IMPACT OF LARVICIDING WITH A BACILLUS THURINGIENSIS ISRAELENSIS FORMULATION, VECTOBAC WG®, ON DENGUE MOSQUITO VECTORS IN A DENGUE ENDEMIC SITE IN

Abstract. The field bioefficacy of a wettable granule (WG) formulation of Bacillus thuringiensis israelensis (Bti), VectoBac WG (Bti strain AM65-52) against dengue vectors, Aedes aegypti and Ae albopictus; was evaluated in a suburban residential area (TST) and in a temporary settlement site (KB) in the state of Selangor, Malaysia. Pre-control ovitrap surveillance of the trial sites indicated a high population of both types of Aedes mosquitoes. The populations were monitored continuously by weekly ovitrapping. Bti was sprayed biweekly at a dosage of 500 g/ha by using a mist-blower. The spray application was targeted into outdoor larval habi-tats. If required, Bti formulation was also applied directly into indoor water-holding containers at 8 g/1,000 l. Based on ovitrap surveillance, a significant reduction in Aedes populations was evident 4 weeks after initiating the first Bti treatment. The ovitrap index (OI) and the larvae density decreased drastically in both trial sites. In TST, the indoor OI was significantly reduced from 57.50±7.50 % to 19.13±5.49 % (p<0.05), while the outdoor OI decreased from 38.89±11.11 % to 15.36±5.93%. In KB, similarly, the OI was significantly reduced by more than half, from 66.66±6.67 % to 30.26±2.99 % (p< 0.05). In all cases, the reduction in OI was paralleled by reduction in larval density